Literature DB >> 2133621

Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs.

B Klinger1, M Garty, A Silbergeld, Z Laron.   

Abstract

The distribution and elimination characteristics (Ke alpha, Ke beta, t1/2) of an intravenous bolus of biosynthetic IGF-I administered to 10 patients with Laron-type dwarfism (LTD, 3 children and 7 adults) and 6 healthy volunteers (3 children and 3 adults) are reported. The mean (+/- SD) endogenous level of IGF-I in the LTD patients was 5.24 +/- 2.77 nM/l and in the controls 27.2 +/- 9.4 nM/l. In the LTD patients the mean elimination constant (Ke beta) was 0.004 +/- 0.001 min-1 and t1/2 = 2.6 +/- 0.7 h, whereas in the controls, Ke beta was 0.003 +/- 0.009 min-1 and the t1/2 = 4.4 +/- 0.5 h (p less than 0.05). The more rapid elimination of injected IGF-I in the LTD patients is assumed to be due to the absence of the GH-dependent 150 kDa IGF-I binding protein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2133621     DOI: 10.1159/000457646

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  5 in total

Review 1.  Clinical use of somatomedin-1: yes or no?

Authors:  Z Laron
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

Review 2.  Somatomedin-1 (insulin-like growth factor-I) in clinical use. Facts and potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

3.  An update on Laron syndrome.

Authors:  Z Laron
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

Review 4.  Insulin-like growth factor 1 (IGF-1): a growth hormone.

Authors:  Z Laron
Journal:  Mol Pathol       Date:  2001-10

Review 5.  GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice.

Authors:  Betina Biagetti; Rafael Simó
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.